Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230857 | 1.00 | SLC18A3 (0.55) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL5760363 | 0.87 | HTR2A (0.61) | HTR2AHTR2CHTR7HTR6KDM4E | |
| SCHEMBL5758023 | 0.79 | HTR2A (0.61) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6008822 | 0.78 | HTR2A (0.60) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3839903 | 0.78 | SLC18A3 (0.59) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL3839897 | 0.78 | SLC18A3 (0.59) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL3839900 | 0.78 | SLC18A3 (0.59) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL8804906 | 0.76 | HRH3 (0.58) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL9721667 | 0.76 | SLC6A3 (0.54) | SLC18A3HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL14318600 | 0.76 | HTR2A (0.81) | HTR2AHTR2CHTR7HTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670379-B2 | Inflammatory or allergic conditions, asthma, inhibition of eosinophil activation, conjunctivitis; (1-((R2-Amino-3-pyridin-3-yl-propyl)-piperidin-4-yl)-(4-fluoro-phenyl) -methanone | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | disclosed |